keyword
Keywords Pulmonary drug delivery animal...

Pulmonary drug delivery animal model

https://read.qxmd.com/read/37015293/development-of-an-inhalable-antiviral-powder-formulation-against-respiratory-syncytial-virus
#21
JOURNAL ARTICLE
Rick Heida, Renate Akkerman, Paulo H Jacob Silva, Anke J Lakerveld, Daniel Ortiz, Chiara Bigogno, Matteo Gasbarri, Puck B van Kasteren, Francesco Stellacci, Henderik W Frijlink, Anke L W Huckriede, Wouter L J Hinrichs
Respiratory viruses including the respiratory syncytial virus (RSV) aggravate the global burden of virus-inflicted morbidity and mortality. Entry inhibitors are a promising class of antiviral drugs for combating these viruses, as they can prevent infection at the site of viral entry, i.e., the respiratory tract. Here we used a broad-spectrum entry inhibitor, composed of a β-cyclodextrin backbone, functionalized with 11-mercapto-1-undecanesulfonate (CD-MUS) that is capable of neutralizing a variety of viruses that employ heparan sulfate proteoglycans (HSPG) to infect host cells...
April 5, 2023: Journal of Controlled Release
https://read.qxmd.com/read/36938947/new-air-jet-dry-powder-insufflator-for-high-efficiency-aerosol-delivery-to-rats
#22
JOURNAL ARTICLE
Rudra Pangeni, Amr Ali Mohamed Hassan, Dale Farkas, Hadi Sudarjat, Worth Longest, Michael Hindle, Qingguo Xu
Pulmonary deposition of lung-targeted therapeutic aerosols can achieve direct drug delivery to the site of action, thereby enhancing the efficacy and reducing systemic exposure. In this study, we investigated the in vitro and in vivo aerosol performance of the novel small animal air-jet dry powder insufflator (Rat AJ DPI) using spray-dried albuterol excipient-enhanced-growth (EEG) powder as a model formulation. The in vitro aerosolization performance of the optimized albuterol EEG powder was first assessed using the Rat AJ DPI...
March 20, 2023: Molecular Pharmaceutics
https://read.qxmd.com/read/36822165/mice-inflammatory-responses-to-inhaled-aerosolized-lps-effects-of-various-forms-of-human-alpha1-antitrypsin
#23
JOURNAL ARTICLE
Kokilavani Sivaraman, Sabine Wrenger, Bin Liu, Dirk Schaudien, Christina Hesse, Gema Gomez-Mariano, Sara Perez-Luz, Katherina Sewald, David DeLuca, Maria J Wurm, Paco Pino, Tobias Welte, Beatriz Martinez-Delgado, Sabina Janciauskiene
Rodent models of lipopolysaccharide (LPS)-induced pulmonary inflammation are used for anti-inflammatory drug testing. We aimed to characterize mice responses to aerosolized LPS alone or with intraperitoneal (i.p.) delivery of alpha1-antitrypsin (AAT). Balb/c mice were exposed to clean air or aerosolized LPS (0.21 mg/mL) for 10 min per day, for 3 d. One hour after each challenge, animals were treated i.p. with saline or with (4 mg/kg body weight) one of the AAT preparations: native (AAT), oxidized (oxAAT), recombinant (recAAT), or peptide of AAT (C-36)...
January 10, 2023: Journal of Leukocyte Biology
https://read.qxmd.com/read/36748276/a-monoclonal-human-alveolar-epithelial-cell-line-arlo-with-pronounced-barrier-function-for-studying-drug-permeability-and-viral-infections
#24
JOURNAL ARTICLE
Patrick Carius, Annemarie Jungmann, Marco Bechtel, Alexander Grißmer, Annette Boese, Gilles Gasparoni, Abdulrahman Salhab, Ralf Seipelt, Klaus Urbschat, Clémentine Richter, Carola Meier, Denisa Bojkova, Jindrich Cinatl, Jörn Walter, Nicole Schneider-Daum, Claus-Michael Lehr
In the development of orally inhaled drug products preclinical animal models regularly fail to predict pharmacological as well as toxicological responses in humans. Models based on human cells and tissues are potential alternatives to animal experimentation allowing for the isolation of essential processes of human biology and making them accessible in vitro. Here, the generation of a novel monoclonal cell line "Arlo," derived from the polyclonal human alveolar epithelium lentivirus immortalized cell line hAELVi via single-cell printing, and its characterization as a model for the human alveolar epithelium as well as a building block for future complex in vitro models is described...
February 7, 2023: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/36575527/nebulization-of-risedronate-alleviates-airway-obstruction-and-inflammation-of-chronic-obstructive-pulmonary-diseases-via-suppressing-prenylation-dependent-ras-erk-nf-%C3%AE%C2%BAb-and-rhoa-rock1-mlcp-signaling
#25
JOURNAL ARTICLE
Di Liu, Wen Xu, Yuan Tang, Jingxue Cao, Ran Chen, Dingwei Wu, Hongpeng Chen, Bo Su, Jinfu Xu
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive disorder that causes airway obstruction and lung inflammation. The first-line treatment of COPD is the bronchodilators of β2-agonists and antimuscarinic drugs, which can help control the airway obstruction, but the long-term use might render the drug tolerance. Bisphosphonates are widely used in osteoclast-mediated bone diseases treatment for decades. For drug repurposing, can delivery of a third generation of nitrogen-containing bisphosphonate, risedronate (RIS) ameliorate the progression of COPD? METHODS: COPD rats or mice models have been established through cigarette-smoking and elastase injection, and then the animals are received RIS treatment via nebulization...
December 28, 2022: Respiratory Research
https://read.qxmd.com/read/36475350/emerging-trends-and-future-challenges-of-nanovaccine-delivery-via-nasal-route
#26
JOURNAL ARTICLE
Hitesh Kumar Dewangan, Akash Raghuvanshi, Kamal Shah
The mucosal surfaces are the key site of the entrance, protection, and stability of several pathogens. Considering that >90% of pathogens gain access to the body via mucosal sites, using mucosal vaccination to generate protective immunity at mucosal sites could overcome. Some of the micro and nano carrier-based nasal delivery systems produce cellular, humoral and mucosal immunity. The nasal route vaccination may protect multiple distant mucosal sites like-rectal, vaginal, oral, and pulmonary. Also, it is a convenient and cost-effective vaccination mode with improved patient compliance...
December 5, 2022: Current Drug Targets
https://read.qxmd.com/read/36376302/flash-drug-release-from-nanoparticles-accumulated-in-the-targeted-blood-vessels-facilitates-the-tumour-treatment
#27
JOURNAL ARTICLE
Ivan V Zelepukin, Olga Yu Griaznova, Konstantin G Shevchenko, Andrey V Ivanov, Ekaterina V Baidyuk, Natalia B Serejnikova, Artur B Volovetskiy, Sergey M Deyev, Andrei V Zvyagin
Tumour microenvironment hinders nanoparticle transport deep into the tissue precluding thorough treatment of solid tumours and metastatic nodes. We introduce an anticancer drug delivery concept termed FlaRE (Flash Release in Endothelium), which represents alternative to the existing approaches based on enhanced permeability and retention effect. This approach relies on enhanced drug-loaded nanocarrier accumulation in vessels of the target tumour or metastasised organ, followed by a rapid release of encapsulated drug within tens of minutes...
November 14, 2022: Nature Communications
https://read.qxmd.com/read/36318785/comparison-of-dose-response-relationships-for-two-isolates-of-sars-cov-2-in-a-nonhuman-primate-model-of-inhalational-covid-19
#28
JOURNAL ARTICLE
Paul A Dabisch, Jaleal S Sanjak, Jeremy A Boydston, John Yeager, Artemas Herzog, Jennifer Biryukov, Katie Beck, Danh Do, Brittany G Seman, Brian Green, Jordan K Bohannon, Brian Holland, David Miller, Taylor Ammons, Denise Freeburger, Susan Miller, Tammy Jenkins, Sherry Rippeon, James Miller, David Clarke, Emmanuel Manan, Ashley Patty, Kim Rhodes, Tina Sweeney, Michael Winpigler, Louis A Altamura, Heather Zimmerman, Alec S Hail, Victoria Wahl, Michael Hevey
Background: As the COVID-19 pandemic has progressed, numerous variants of SARS-CoV-2 have arisen, with several displaying increased transmissibility. Methods: The present study compared dose-response relationships and disease presentation in nonhuman primates infected with aerosols containing an isolate of the Gamma variant of SARS-CoV-2 to the results of our previous study with the earlier WA-1 isolate of SARS-CoV-2. Results: Disease in Gamma-infected animals was mild, characterized by dose-dependent fever and oronasal shedding of virus...
November 1, 2022: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://read.qxmd.com/read/36263591/pulmonary-delivery-of-curcumin-loaded-glycyrrhizic-acid-nanoparticles-for-anti-inflammatory-therapy
#29
JOURNAL ARTICLE
Chunxian Piao, Chuanyu Zhuang, Minji Kang, Jihun Oh, Minhyung Lee
Acute lung injury (ALI) is an inflammatory disease of the lungs. Curcumin (Cur) shows protective effects in ALI animal models. However, Cur is a hydrophobic drug and its administration into the lungs is inefficient due to its low bioavailability. In this study, glycyrrhizic acid (GA) micelles were produced and evaluated as a carrier of Cur for treatment of ALI. Cur-loaded GA (GA-Cur) nanoparticles were produced using an oil-in-water emulsion/solvent evaporation method. The size and surface charge of the GA-Cur nanoparticles were 159 nm and -23 mV, respectively...
October 20, 2022: Biomaterials Science
https://read.qxmd.com/read/36255136/nuclear-medicine-imaging-methods-as-novel-tools-in-the-assessment-of-pulmonary-drug-disposition
#30
JOURNAL ARTICLE
Severin Mairinger, Irene Hernández-Lozano, Markus Zeitlinger, Carsten Ehrhardt, Oliver Langer
INTRODUCTION: : Drugs for the treatment of respiratory diseases are commonly administered by oral inhalation. Yet surprisingly little is known about the pulmonary pharmacokinetics of inhaled molecules. Nuclear medicine imaging techniques (i.e. planar gamma scintigraphy, single-photon emission computed tomography [SPECT] and positron emission tomography [PET]) enable the non-invasive dynamic measurement of the lung concentrations of radiolabeled drugs or drug formulations. This review discusses the potential of nuclear medicine imaging techniques in inhalation biopharmaceutical research...
October 18, 2022: Expert Opinion on Drug Delivery
https://read.qxmd.com/read/36237747/a-novel-agnostic-respiratory-stimulant-as-a-treatment-for-apnea-of-prematurity-a-proof-of-concept-study
#31
JOURNAL ARTICLE
Thomas L Miller, Lynn M Raab, Thomas H Shaffer, Alfred Schweikert, Frank Diana, Prem Fort, Alana S Frum, Joseph Pergolizzi, Robert B Raffa
AIM/OBJECTIVE: ENA-001 is a novel selective antagonist of large-conductance BK (big potassium) channels located in the carotid bodies, where they act as chemoreceptors that sense low arterial oxygen levels and establish a feedback loop to brainstem nuclei responsible for initiating spontaneous breathing and maintaining adequate oxygen to tissues. ENA-001 attenuates respiratory depression induced by a variety of chemical agents, essentially "agnostic" to the precipitating drug (e...
September 2022: Curēus
https://read.qxmd.com/read/36131190/a-review-of-formulations-and-preclinical-studies-of-inhaled-rifampicin-for-its-clinical-translation
#32
JOURNAL ARTICLE
Prakash Khadka, Jack Dummer, Philip C Hill, Rajesh Katare, Shyamal C Das
Inhaled drug delivery is a promising approach to achieving high lung drug concentrations to facilitate efficient treatment of tuberculosis (TB) and to reduce the overall duration of treatment. Rifampicin is a good candidate for delivery via the pulmonary route. There have been no clinical studies yet at relevant inhaled doses despite the numerous studies investigating its formulation and preclinical properties for pulmonary delivery. This review discusses the clinical implications of pulmonary drug delivery in TB treatment, the drug delivery systems reported for pulmonary delivery of rifampicin, animal models, and the animal studies on inhaled rifampicin formulations, and the research gaps hindering the transition from preclinical development to clinical investigation...
September 21, 2022: Drug Delivery and Translational Research
https://read.qxmd.com/read/35882740/feasibility-studies-of-nebulized-sars-cov-2-neutralizing-antibody-in-mice-and-cynomolgus-monkeys
#33
JOURNAL ARTICLE
Jilei Jia, Zhaojuan Yin, Xiao Zhang, Huimin Li, Dan Meng, Qianqian Liu, Hongfang Wang, Meng Han, Shixiang Suo, Yan Liu, Ping Hu, Chunyun Sun, Jing Li, Liangzhi Xie
PURPOSE: Neutralizing antibodies, administrated through intravenous infusion, have shown to be highly efficacious in treating mild and moderate COVID-19 caused by SARS-CoV-2 infection in the lung. However, antibodies do not transport across the plasma-lung barrier efficiently, and up to 100 mg/kg dose was used in human causing significant supply and cost burdens. This study was to explore the feasibility of nebulized antibodies inhalation delivery as an alternative route. METHODS: HB27, a potent RBD-specific humanized monoclonal antibody (Zhu et al...
July 26, 2022: Pharmaceutical Research
https://read.qxmd.com/read/35834639/radiolabeling-methods
#34
REVIEW
Myrna B Dolovich
In vivo measurements of the deposition of an inhaled radiolabeled pharmaceutic have provided useful information related to the inhaler efficiency for depositing drug in the lung. A number of labeling techniques have been developed and applied to pharmaceutical aerosols delivered by pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) and nebulizers; the choice of radiotracer depends on the type of imaging study being performed and the equipment used to image the lung. Preparation, validation and calibration of the radiolabeled pharmaceutical product is key to successful interpretation of the imaging study...
August 2022: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://read.qxmd.com/read/35726420/alternative-methods-for-pulmonary-administered-drugs-metabolism-a-breath-of-change
#35
REVIEW
Érika Yoko Suzuki, Alice Simon, Thaisa Francielle Souza Domingos, Bárbara de Azevedo Abrahim Vieira, Alessandra Mendonça Teles de Souza, Carlos Rangel Rodrigues, Valeria Pereira de Sousa, Flávia Almada do Carmo, Lucio Mendes Cabral
Prediction of pulmonary metabolites following inhalation of a locally acting pulmonary drug is essential to the successful development of novel inhaled medicines. The lungs present metabolic enzymes, therefore they influence drug disposal and toxicity. The present review provides an overview of alternative methods to evaluate the pulmonary metabolism for the safety and efficacy of pulmonary delivery systems. In vitro approaches for investigating pulmonary drug metabolism were described, including subcellular fractions, cell culture models and lung slices as the main available in vitro methods...
2023: Mini Reviews in Medicinal Chemistry
https://read.qxmd.com/read/35636615/novel-drug-delivery-systems-and-disease-models-for-pulmonary-fibrosis
#36
REVIEW
Rui Li, Yizhen Jia, Xiaohan Kong, Yichu Nie, Yang Deng, Yang Liu
Pulmonary fibrosis (PF) is a serious and progressive lung disease which is possibly life-threatening. It causes lung scarring and affects lung functions including epithelial cell injury, massive recruitment of immune cells and abnormal accumulation of extracellular matrix (ECM). There is currently no cure for PF. Treatment for PF is aimed at slowing the course of the disease and relieving symptoms. Pirfenidone (PFD) and nintedanib (NDNB) are currently the only two FDA-approved oral medicines to slow down the progress of idiopathic pulmonary fibrosis, a specific type of PF...
June 3, 2022: Journal of Controlled Release
https://read.qxmd.com/read/35538809/genistein-in-the-treatment-of-hypertension-a-review
#37
JOURNAL ARTICLE
Paulina Sigowska, Michał Zimoch, Aleksandra Baska, Jakub Kazik, Kamil Leis, Grzegorz Grześk
Genistein, a natural compound, belonging to the group of isoflavones has a confirmed positive effect in such diseases like hormone-dependent cancers, osteoporosis, and cardiovascular diseases, including arterial and pulmonary hypertension. The multiway hypotensive effect is based on vasodilation with simultaneous inhibition of vasoconstriction, and RAA interference. It impacts both vascular smooth muscles and endothelium due to its influence on many molecular pathways and peptides; among them: protection against oxidative stress, RhoA/Rho pathway inhibition, enhancing cAMP activation, modification of cellular calcium influx, and the increase of eNOS concentrations...
May 10, 2022: Endocrine, Metabolic & Immune Disorders Drug Targets
https://read.qxmd.com/read/35451894/pulmonary-delivery-of-a-recombinant-rage-antagonist-peptide-derived-from-high-mobility-group-box-1-in-a-bleomycin-induced-pulmonary-fibrosis-animal-model
#38
JOURNAL ARTICLE
Chunxian Piao, Chuanyu Zhuang, Min Kyung Ko, Do Won Hwang, Minhyung Lee
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by irreversible fibrosis and destruction of the alveolar structure. Receptor for advanced glycation end products (RAGE) has been identified as one of the key molecules involved in IPF pathogenesis. A RAGE-antagonist peptide (RAP) was developed based on the RAGE-binding domain of high mobility group box-1 (HMGB-1). Anti-IPF effects of RAP were evaluated in a bleomycin-induced mouse model of IPF. Bleomycin was administered intratracheally, and then RAP was administrated twice by intratracheal instillation, 1 and 3 d after bleomycin challenge...
August 2022: Journal of Drug Targeting
https://read.qxmd.com/read/35422652/experimental-and-theoretical-insights-on-chemopreventive-effect-of-the-liposomal-thymoquinone-against-benzo-a-pyrene-induced-lung-cancer-in-swiss-albino-mice
#39
JOURNAL ARTICLE
Arif Khan, Mohammed A Alsahli, Mohammad A Aljasir, Hamzah Maswadeh, Mugahid A Mobark, Faizul Azam, Khaled S Allemailem, Faris Alrumaihi, Fahad A Alhumaydhi, Ahmad A Almatroudi, Naif AlSuhaymi, Masood A Khan
Purpose: Thymoquinone (TQ), a phytoconstituent of Nigella sativa seeds, has been studied extensively in various cancer models. However, TQ's limited water solubility restricts its therapeutic applicability. Our work aims to prepare the novel formulation of TQ and assess its chemopreventive potential in chemically induced lung cancer animal model. Methods: The polyethylene glycol coated DOPE/CHEMS incorporating TQ-loaded pH-sensitive liposomes (TQPSL) were prepared and characterized...
2022: Journal of Inflammation Research
https://read.qxmd.com/read/34784868/carbon-monoxide-as-a-therapeutic-for-airway-diseases-contrast-and-comparison-of-various-co-delivery-modalities
#40
REVIEW
Ravi Tripathi, Xiaoxiao Yang, Stefan W Ryter, Binghe Wang
The quest to find novel strategies to tackle respiratory illnesses has led to the exploration of the potential therapeutic effects of carbon monoxide (CO) as an endogenous signaling molecule and a cytoprotective agent. Further, several studies have demonstrated the pharmacological efficacy of CO in animal models of respiratory disorders, such as acute lung injury and pulmonary hypertension. Because of the gaseous nature of CO and its affinity for multiple targets, its controlled delivery has been a challenge...
2021: Current Topics in Medicinal Chemistry
keyword
keyword
52496
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.